Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.
Masamichi KimuraEiichi OgawaKenichi HaradaJun ImamuraMasanao SaioYoshihiro IkuraHiroshi YatsuhashiKazumoto MurataKouichi MiuraIchiro IeiriAtsushi TanakaKiminori KimuraPublished in: BMJ open gastroenterology (2022)
NCT04047160.